Breakthrough MS drug uses green mamba venom discovery to promote myelin repair

Ten years of work, and a little help from the green mamba snake, has resulted in a promising new drug that is already being tested in clinical trials.

Verve won trial success with a gene-editing milestone. Why don’t investors like it?

This weekend, Verve Therapeutics presented the first-ever results of an in vivo base editing therapy in humans, marking a major milestone not only for the

November 15, 2023

Novel Goalpost for PCI Excellence Is Borrowed From the Surgeons

Researchers made a case for failure to rescue (FTR) as a potential quality metric in percutaneous coronary intervention (PCI), using records from a large nationwide

July 13, 2024

Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts

Good morning, everyone, and how are you today? We are doing just fine, thank you. After all, the birds are still chirping and a cool

October 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.